Trial of 177Lu-PSMA-617 (Pluvicto) in PSMA-Positive mCRPC with Super Scan Bone Metastases

This study evaluates the safety, tolerability, and optimal dosing of Pluvicto—a PSMA-directed beta emitter radiation conjugate—in men with progressive metastatic castration-resistant prostate cancer (mCRPC) exhibiting a “super scan” bone metastasis pattern, addressing a key patient subset previously excluded from VISION. Up to 30 patients with prior ARAT and 2nd line+ treatment histories will be enrolled.